<?xml version="1.0" encoding="UTF-8"?>
<p>Fluorescence microscopy was also used to further evaluate the viral infection rate for optimal drug combinations and the nonoptimal drug combinations (
 <bold>Figure</bold>
 <xref rid="adtp202000034-fig-0005" ref-type="fig">
  <bold>5</bold>
 </xref>). Of note, no apparent adverse effects cell density for Optimal Combo 1 and 2 were observed. The identification and validation process implemented during Project IDentif.AI demonstrated that rapid optimization of the combination therapy development roadmap could be completed within 3 days (
 <bold>Figure</bold>
 <xref rid="adtp202000034-fig-0006" ref-type="fig">
  <bold>6</bold>
 </xref>).
</p>
